Navigation Links
Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
Date:5/16/2011

INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 30 studies at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., from June 3 – 7, 2011, including results from PARAMOUNT, a Phase III study of an ALIMTA-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.  PARAMOUNT data will be included in the ASCO-sponsored press briefing the morning of June 5 followed by a presentation during the Lung Cancer Oral Abstract Session at ASCO later the same day.

At ASCO, Lilly will present the latest research results on ALIMTA® (pemetrexed for injection) and GEMZAR® (gemcitabine for injection), as well as ERBITUX® (cetuximab) with partners Bristol-Myers Squibb and Merck KGaA.

"Lilly Oncology is committed to exploring innovations that improve outcomes for all people living with cancer," said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology.  "We believe that data from PARAMOUNT, and our other studies at ASCO, demonstrate Lilly's focus on tailored therapies, and commitment to addressing unmet needs in cancer care."

ALIMTA Oral Abstract Session:

  • Abstract # CRA7510: Sunday, June 5, 2011, 11:30 - 11:45 AM
    • PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
    • Author/Speaker: L. G. Paz-Ares, F. de Marinis, M. Dedui, M. Thomas, J.P. Pujol, P. Bidoli, O. Molinier, T.P. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C. Visseren-Grul, C. Gridelli
    • Location: Hall D1

P-LLY

This press release contains forward-looking statements about the potential of ALIMTA and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011
2. Amylin Pharmaceuticals Files Suit Against Eli Lilly
3. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
4. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
5. Lilly and Medtronic Announce Drug-Device Collaboration for Parkinsons Disease
6. Lilly Declares Second-Quarter 2011 Dividend
7. Lilly Reports First-Quarter 2011 Results
8. Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency
9. Avant Healthcare Marketing Receives 2010 Lilly Global Sustained Supplier Award
10. Lilly Confirms Date and Conference Call for First-Quarter 2011 Financial Results Announcement
11. Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):